Massachusetts-based Moderna, Inc. today announced the first participant had been dosed in the Eclipse Phase 1 study of mRNA-1189, the Company's Epstein-Barr Virus (EBV) vaccine candidate.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,